Travere director gets stock and option awards

Meckler Jeffrey A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Meckler Jeffrey A reported acquisition or exercise transactions in this Form 4 filing.

Travere Therapeutics director Jeffrey A. Meckler received new equity compensation. He was granted 4,000 shares of common stock and 12,000 stock options as an automatic equity grant under Travere’s 2018 Equity Incentive Plan and non-employee director compensation program.

The options give him the right to buy 12,000 shares of common stock at $42.26 per share and expire on May 19, 2036. The equity award vests over a one year period. After the grant, he directly owns 91,500 common shares and holds 12,000 stock options.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 2 txns

Insider Meckler Jeffrey A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 12,000 contracts (Direct); Common Stock — 91,500 shares (Direct)

Footnotes (2)

1. F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. F2. The equity award vests over a one year period.

Key Figures

Common stock grant: 4,000 shares Stock options granted: 12,000 options Option exercise price: $42.26/share +3 more

6 metrics

Common stock grant 4,000 shares Automatic equity grant on May 19, 2026

Stock options granted 12,000 options Right to buy common stock granted May 19, 2026

Option exercise price $42.26/share Conversion or exercise price for 12,000 options

Option expiration May 19, 2036 Expiration date of the stock options

Shares owned after grant 91,500 shares Common stock directly owned following the transaction

Options held after grant 12,000 options Total stock options directly held following the transaction

Key Terms

Automatic equity grant, 2018 Equity Incentive Plan, non-employee director compensation program, equity award vests over a one year period, +1 more

5 terms

Automatic equity grant financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

2018 Equity Incentive Plan financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

non-employee director compensation program financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

equity award vests over a one year period financial

"The equity award vests over a one year period."

Stock option (right to buy) financial

"Stock option (right to buy) listed as a derivative security with 12,000 underlying shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Travere Therapeutics (TVTX) director Jeffrey Meckler receive in this Form 4?

Jeffrey Meckler received an automatic equity grant consisting of 4,000 shares of Travere Therapeutics common stock and 12,000 stock options. These awards were made under the company’s 2018 Equity Incentive Plan and its non-employee director compensation program.

Are Jeffrey Meckler’s new Travere (TVTX) awards open-market purchases?

No, the Form 4 shows compensation awards, not open-market purchases. The 4,000 shares and 12,000 options were granted automatically under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program.

What are the key terms of Jeffrey Meckler’s new Travere (TVTX) stock options?

The stock options cover 12,000 shares of Travere common stock at a $42.26 exercise price. They expire on May 19, 2036. The underlying equity award vests over a one year period, according to the disclosure footnote.

How many Travere (TVTX) shares does Jeffrey Meckler hold after this Form 4?

After the equity grant, Jeffrey Meckler directly owns 91,500 shares of Travere Therapeutics common stock, plus 12,000 stock options. The filing reports these as his direct holdings following the May 19, 2026 transactions.

How quickly do Jeffrey Meckler’s Travere (TVTX) equity awards vest?

The filing states that the equity award vests over a one year period. This means the granted equity becomes fully vested during that year, consistent with the terms described in the non-employee director compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meckler Jeffrey A

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		4,000(1)(2)	A	$0	91,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$42.26	05/19/2026		A		12,000(1)		05/19/2027(2)	05/19/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

2. The equity award vests over a one year period.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)